Hi-bio, A Biogen Company
Clinical trials sponsored by Hi-bio, A Biogen Company, explained in plain language.
A Biogen subsidiary developing therapies for immunology and inflammation.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New antibody drug targets kidney damage in lupus patients
Disease control CompletedThis early-stage study tests a drug called felzartamab in 14 people with active lupus nephritis, a kidney condition caused by lupus. The drug is a lab-made antibody designed to lower harmful antibody buildup in the kidneys. The main goal is to check safety and how the drug works …
Phase: PHASE1 • Sponsor: HI-Bio, A Biogen Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody drug shows promise for kidney disease
Disease control CompletedThis Phase 2 trial tested a drug called felzartamab in 54 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug targets immune cells to reduce protein leakage in urine, a sign of kidney damage. The study compared felzartamab to a placebo to see i…
Phase: PHASE2 • Sponsor: HI-Bio, A Biogen Company • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC